



DOI: 10.22363/2313-0245-2023-27-3-391-402

EDN: PYFVNB

ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ

ORIGINAL RESEARCH

## Long exposure impact of antibiotics subinhibitory doses and silver nanoparticles on uropathogenic bacteria

Manga J.A. Mbarga  , Razan Marouf , Irina V. Podoprigora ,  
Kitio L.D. Anyutoulou , Yuri V. Chapurin , Irina N. Sharova 

RUDN University, Moscow, Russian Federation

 josepharsenembarga@yahoo.fr

**Abstract. Relevance.** Although the primary purpose of using antibiotics is to treat infectious diseases, their misuse gradually leads to loss of their effectiveness. *The aim* of the current investigation was to explore the changes that occur in uropathogenic bacteria after long exposure to antimicrobials. *Materials and Methods.* We compared the effects of long-term exposure to ampicillin, cefazoline, kanamycin and silver nanoparticles (AgNPs) on susceptibility, biofilm formation and planktonic bacteria in 4 clinical uropathogenic strains namely *Escherichia coli* (UPEC), *Staphylococcus aureus* (*S. aureus*), *Enterococcus faecalis* (*E. faecalis*) and *Streptococcus agalactiae* (*St. agalactiae*). The minimum inhibitory concentrations (MIC) were determined using the microplate microdilution method and bacteria were exposed to increasing concentrations of each antimicrobial (from MIC/2 to MIC) prepared in the brain heart infusion broth for 8 days. The susceptibility of bacteria to antibiotics was assessed using the Kirby Bauer disc diffusion method and the biofilm formation was assessed using crystal violet bacterial attachment assay. *Results and Discussion.* The data in this investigation highlight that long-term exposure to antimicrobials may induce changes in susceptibility to other antibiotics and biofilm formation in Uropathogenic strains. Indeed, exposure to ampicillin made *E. faecalis* resistant to ceftazidime and *St. agalactiae* resistant to tetracycline, ceftazidime/clavulanate and ceftazidime. Following exposure to cefazolin, a significant decrease in susceptibility was observed in *E. coli* to ceftazidime/clavulanate and ceftazidime while *S. aureus* became resistant to ceftazidime/clavulanate, ceftazidime and to ceftriaxone. Similar variations were observed on *St. agalactiae* and *E. faecalis*, which in addition to the 3 antibiotics above-mentioned, have become resistant to tetracycline. The most significant variations in susceptibility to antibiotics were observed following exposure to kanamycin: *E. coli* developed resistance to ceftazidime and a decrease in sensitivity was noted on ceftazidime/clavulanate while *S. aureus*, *E. faecalis* and *St. agalactiae* all 3 became resistant to ceftazidime/clavulanate and ceftazidime. In addition, except for *E. coli* all the bacteria in this investigation which had undergone successive passages in AgNPs developed resistance to ceftazidime/clavulanate and ceftazidime. Bacteria exposed to ampicillin and cefazolin produced more biofilms than their respective controls. *Conclusion.* Long term exposure of uropathogens to antibiotics and AgNPs induces significant changes in susceptibility to other antibiotics and biofilm formation and antibiotics should therefore only be used when necessary.

**Key words:** long exposure, antibiotics, silver nanoparticles, biofilm, adaptation

Mbarga M.J.A., Marouf R., Podoprigora I.V., Anyutoulou K.L.D., Chapurin Y.V., Sharova I.N., 2023



This work is licensed under a Creative Commons Attribution 4.0 International License  
<https://creativecommons.org/licenses/by-nc/4.0/legalcode>

**Funding.** The authors received no financial support for the research, authorship, and publication of this article.

**Author contributions.** Mbarga M.J.A — concept and design of research, literature review, data processing collection and processing of materials; Podoprigora I.V. — design of research, writing text; Anyutoulou K.L.D and Marouf R. — concept of research, data processing collection and processing of materials; Chapurin Y.V. and Sharova I.N. — statistical data processing, writing text. All authors have made significant contributions to the development concepts, research, and manuscript writing, read and approved final version before publication.

**Conflict of interest statement.** The authors declare no conflict of interest.

**Ethics approval** — not applicable.

**Acknowledgements** — this study has been supported by the RUDN University strategic Academic Leadership Program.

**Consent for publication** — not applicable.

Received 17.11.2022. Accepted 15.02.2023.

**For citation:** Mbarga MJA, Marouf R, Podoprigora IV, Anyutoulou KLD, Chapurin YV, Sharova IN. Long exposure impact of antibiotics subinhibitory doses and silver nanoparticles on uropathogenic bacteria. *RUDN Journal of Medicine*. 2023;27(3):391—402. doi: 10.22363/2313-0245-2023-27-2-391-402

## Introduction

The use of antibiotics is essential in the treatment of infectious diseases of bacterial origin [1,2] including urinary tract infections (UTIs). UTIs are caused by so-called uropathogenic microorganisms, most often commensal bacteria or fungi, which under certain conditions can become pathogenic [3]. 80 to 90 % of UTIs are caused by so-called Uropathogenic *Escherichia coli* (UPEC) while other species such as *Staphylococcus saprophyticus*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Acinetobacter baumannii*, *Streptococcus* and *Enterococcus* are less rarely involved [3, 4].

UTIs are usually treated by antibiotics such as trimethoprim-sulfamethoxazole (TMP-SMX), nitrofurantoin or Fosfomycin for acute uncomplicated urinary tract infections [5]. Since resistance to TMP-SMX and ciprofloxacin preclude their use as empiric treatment for UTIs in patients who were previously exposed to them or who are at risk to be infected with extended-spectrum  $\beta$ -lactamases (ES-BLs)-producing bacteria [6], other antibiotics are sometimes used in second line and generally include oral cephalosporins (fluoroquinolones, cefixime) and  $\beta$ -lactams (amoxicillin-clavulanate) [6]. Notwithstanding this multitude of choices in terms of antibiotics, due to attitudes of self-medication,

taking antibiotics without prior antibiogram and all negligent behavior related to the misuse of antibiotics, the resistance of bacteria to antibiotics has grown meteorically worldwide [7, 8]. Although this problem is progressively leading to the general mobilization for the research of new antimicrobial compounds and alternative ways of fighting bacterial infections, the mechanisms of this resistance are better and better elucidated but the direct implication of the consumption of antibiotic has not yet been totally established.

While previous investigations have focused on the consequences of long-term exposure to commonly used biocides such as polyhexamethylene biguanide (PHMB), triclosan, benzalkonium chloride (BAC) on the antimicrobial susceptibility of many clinical isolates including uropathogens [9–11], there are currently not enough investigations into the multiple phenotypic consequences that can occur due to long-term exposure to antibiotics and silver nanoparticles. Therefore, the present study aimed to assess the effects of long-term exposure to ampicillin, kanamycin, cefazoline and AgNPs in four Uropathogenic clinical isolates namely *E. coli* (UPEC), *S. aureus*, *E. faecalis* and *St. agalactiae*. The variations induced on the susceptibility to other antibiotics was evaluated as well as the biofilm formation and planktonic bacteria.

## Materials and methods

### Bacterial strains and culture conditions

This investigation included 4 previously isolated Uropathogenic strains namely *E. coli*, *S. aureus*, *E. faecalis* and *St. agalactiae*, all provided by the laboratory of microbiology and virology of the RUDN University. Bacteria were cultured on BHIB (Brain Heart Infusion Broth) (HIMEDIA®, Ref 173–500G) and Muller Hinton Agar (MHA) (HIMEDIA®, Ref 173–500G) and incubated aerobically at 37 °C for 18–24h.

### Stocks solution of antibiotics and AgNPs

Stock solutions of each antimicrobial were prepared at a concentration of 1024 µg/ml and dilutions were made as needed. Ampicillin, cefazolin, and kanamycin were prepared in physiological water (NaCl 0,9 %) and 2 nm silver nanoparticles (Nanoserebro Argitos, OONPP Sintek Nano, Russia) were prepared in distilled water. All the solutions were sterilized by microfiltration (0.45 µm) prior to use.

### Susceptibility of bacteria to antibiotics

The modified Kirby-Bauer's disc method described in our previous study [12] was used to assess the susceptibility to antibiotics of uropathogenic strains used. Briefly, after bringing the bacteria to room temperature, they were cultured at 37 °C for 24 hours in sterile BHIB. 1.5 ml of each overnight culture was centrifuged (Eppendorf Centrifuge 5415 R) for 10 minutes at 3000 RCF and the centrifugate was collected, washed 3 times with Phosphate buffer saline (PBS) and resuspended in 5ml of physiological water to obtain a concentration equivalent to 0.5 McFarland. 100µL of the culture was plated on Muller Hinton Agar (MHA) (HIMEDIA®, Ref 173–500G) and the antibiotic discs were placed aseptically using a dispenser. After 18–24 hours of incubation, the inhibition diameters were measured and interpreted referred to the Clinical & Laboratory Standards Institute [13]. The petri dishes were again incubated for 48 hours at 37 °C and the bacteria of the second growth in the inhibition zones were isolated and subjected to a second antibiogram as described above. The 8 antibiotics used were: tetracyclin (TE), 30 µg/disc, cefazolin/ clavulanic acid (CAC), 30/10 per disc;

ceftazidime (CAZ), 30 µg/disc; ceftriaxone (CTR), 30 µg/disc; ciprofloxacin (CIP), 30 µg/disc; imipenem (IMP), 10 µg/disc; nitrofurantoin (NIT), 200 µg/disc and trimethoprim (TR), 30 µg/disc.

### Determination of minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC)

MICs of antibiotics and AgNPs on the 4 bacteria tested were determined by microbroth dilution method as previously described [14]. Briefly, all the stock solutions above-mentioned were submitted to serial twofold dilutions in BHI broth sterile U-bottom 96-well microplates. 100 µL of broth were added in all the wells of the plates and 100µL silver nanoparticles or antibiotics (1024mg/mL) were added in the first line. 100 µL of sterile distilled water was added in column 11 and 12. Then serial dilutions were performed by passing 100 µL of wells of the line A to the wells of line B and so forth. In each test hole 10 µL of the respective inoculum was added (with turbidity equivalent to a 0.5 McFarland scale). In the column 11, 10 µL of saline solution was added (0.9 %) and served as positive control while column 12, where 10µL of inoculum was added served as the negative control. Finally, plates were covered and incubated at 37 °C for 24 h. After incubation, MIC was considered as the lowest concentration that inhibited the visible growth of bacteria. Further, MBCs were determined by subculturing the wells without visible growth (with concentrations  $\geq$  MIC) on MHA plates. Inoculated agar plates were incubated at 37 °C for 24 h. MBC was considered as the lowest concentration that did not give any bacterial growth on agar.

### Long-term exposure of bacteria to antibiotics and silver nanoparticles

Bacteria were exposed to increasing concentrations of ampicillin, cefazolin, kanamycin and AgNPs using U-bottom 96-well microplates. 8 concentrations of each antimicrobial were prepared in sterile BHIB then the mixture was sterilized by microfiltration prior to use. The concentrations varied from MIC/2 to MIC with an increment of MIC/16. For each antimicrobial, 200 µL of the preparation of MIC/2

concentration was introduced into line 1 of the microplate, then MIC/2 + 2MIC/16 in line 2, MIC/2 + 3MIC/16 in line 3 ... and MIC in line 8. 15 µL of overnight culture of each bacterium prepared at a concentration equivalent to 0.5 of McFarland was inoculated in the first line and after 24H of incubation at 37 °C, the wells of line 1 were homogenized and 15 µL was transferred to line 2 of the corresponding columns and the same operation was repeated for the following lines until the 8th day. Bacteria passaged 8 times on antimicrobial-free medium were also included and were considered as the controls. During incubation, the microplates were placed in a container containing distilled water to limit water loss by evaporation. After successive passages, the bacteria were kept at –80 °C in cryovials (Cryoinstant; Deltalab, Spain) for subsequent testing. The antibiotic sensitivity of the bacteria obtained was evaluated exactly as described above.

#### **Evaluation of biofilm formation by crystal violet bacterial attachment assay**

The biofilm formation of original strains and exposed strains was assessed in sterile 96-well microtiter plate [15]. 200 µL of sterile BHIB was introduced in each well and was inoculated by the corresponding overnight culture (18 to 24 h at 37 °C and 100 rpm) centrifugated and resuspended in physiological water to obtain a turbidity equivalent to 0.5 of McFarland as described above. Sterile controls were also included. The plates were incubated statically for 48 h at 37 °C. 100 µL of the medium was transferred in the corresponding well in another microtiter plate for planktonic measurement. The remaining medium was removed from the wells and replaced with 200 µL of 1 % (w/v) crystal violet solution during 90 s. The wells were rinsed three times with distilled water prior to drying at 37 °C. The biofilm-bound crystal violet was solubilized in 200 µL of 100 % ethanol and the A450 was determined and compared with the negative controls. Each test was repeated 4 times and each repeat was read 3 times.

#### **Planktonic measurement**

Free bacteria were assessed simultaneously with the biofilm assay. The 100 µL of medium transferred to another microtiter plate during the biofilm formation

test were diluted with 100 µL of physiological water. Free bacteria were evaluated by determining A450 and compared with the negative controls [16].

#### **Statistical analysis**

All experiments were carried out at least in triplicate. The statistical significance was set at  $p \leq 0,05$ . T-test, principal component analysis (PCA) and Ascending Hierarchical Classification (AHC) were carried out using the statistical software XLSTAT 2020 (Addinsoft Inc., New York, USA). All the other graphs were plotted by Excel software or SigmaPlot 12.5 (Systat Software, San Jose, CA, USA)

#### **Results and discussion**

Bacteria resulting from the second growth in the inhibition zone after antibiogram are more resistant to certain antibiotics than the parent strains.

The antibiogram is a test to assess the susceptibility of bacteria to antibiotics and should always be done before any prescription for antibiotics [17]. It often happens that some bacteria, although sensitive to antibiotics, present a second growth zone, which could be explained on the one hand by the loss of the bacteriostatic effect of the antimicrobial considered and on the other hand, by the acquisition of resistance of the bacteria tested after long exposure to the antibiotic. During this investigation, we carried out an antibiogram of 4 uropathogenic strains and after 24 hours of incubation, the diameters of inhibition were measured then the petri dishes were again incubated for 48 hours and the colonies which grew inside the inhibition zones were recovered. These colonies were grown and a second antibiogram was performed. The results presented on Table 1 show the antibiotic sensitivity of the uropathogens used and their analogues and the variations rates of inhibition diameters relative to the parent strains. No colony was observed in the inhibition zone of *St agalactiae* whereas this was the case with *S. aureus*, *E. coli* and *E. faecalis*. Except for EC-CTR (*E. coli* isolated from the inhibition zone of Ceftriaxone), the greatest variations were observed in bacteria isolated from inhibition zone of ceftriaxone, ceftazidime and ceftazidime/clavulanate. The SA-CTR 1 strain became resistant to ceftriaxone, ceftazidime/clavulanate and even more resistant to ceftazidime (Table 1).

Similar variations were observed in SA-CAZ and EF-TR, but EF-TR did not become resistant to ceftriaxone. Numerous recent investigations have highlighted that changes in sensitivity such as those observed in this study were mainly due to the very strong adaptability of bacteria in stressful environments [18–23]. Alarming, the results of

this study and those of similar other recent investigations show that changes can be induced in bacteria over a very short period of exposure to antibiotics and highlight the importance of taking antibiotics only when necessary, under prescription and after an antibiogram.

Table 1

Sensitivity to antibiotics of uropathogens and their analogues isolated from the second growth in the inhibition zone

Strain	Parameter	TE	CAZ	CTR	CAC	TR	CIP	NIT	IMP	
<i>S. aureus</i>	<i>S. aureus</i>	-	12 <sup>R</sup>	12 <sup>R</sup>	25 <sup>S</sup>	16 <sup>I</sup>	6 <sup>R</sup>	26 <sup>S</sup>	21 <sup>S</sup>	29 <sup>S</sup>
	SA-CAC 1	CAC	12 <sup>R</sup>	13 <sup>R</sup>	21 <sup>S</sup>	12 <sup>R</sup>	6 <sup>R</sup>	22 <sup>S</sup>	18 <sup>S</sup>	23 <sup>S</sup>
	SA-CAC 2	CAC	12 <sup>R</sup>	14 <sup>R</sup>	20 <sup>I</sup>	12 <sup>R</sup>	6 <sup>R</sup>	23 <sup>S</sup>	19 <sup>S</sup>	24 <sup>S</sup>
	SA-CTR 1	CTR	13 <sup>R</sup>	6 <sup>R</sup>	6 <sup>R</sup>	6 <sup>R</sup>	6 <sup>R</sup>	23 <sup>S</sup>	18 <sup>S</sup>	22 <sup>S</sup>
	SA-CTR 2	CTR	12 <sup>R</sup>	12 <sup>R</sup>	23 <sup>S</sup>	12 <sup>R</sup>	6 <sup>R</sup>	23 <sup>S</sup>	24 <sup>S</sup>	24 <sup>S</sup>
	SA-CAZ	CAZ	13 <sup>R</sup>	6 <sup>R</sup>	6 <sup>R</sup>	6 <sup>R</sup>	6 <sup>R</sup>	26 <sup>S</sup>	21 <sup>S</sup>	26 <sup>S</sup>
	SA-TE	TE	12 <sup>R</sup>	13 <sup>R</sup>	20 <sup>I</sup>	13 <sup>R</sup>	6 <sup>R</sup>	23 <sup>S</sup>	20 <sup>S</sup>	24 <sup>S</sup>
<i>E. coli</i>	<i>E. coli</i>	-	8 <sup>R</sup>	23 <sup>S</sup>	25 <sup>S</sup>	22 <sup>S</sup>	6 <sup>R</sup>	24 <sup>S</sup>	22 <sup>S</sup>	27 <sup>S</sup>
	EC-TR	TR	6 <sup>R</sup>	21 <sup>S</sup>	26 <sup>S</sup>	23 <sup>S</sup>	6 <sup>R</sup>	26 <sup>S</sup>	21 <sup>S</sup>	23 <sup>S</sup>
<i>E. faecalis</i>	<i>E. faecalis</i>	-	15 <sup>I</sup>	17 <sup>I</sup>	22 <sup>S</sup>	17 <sup>I</sup>	29 <sup>S</sup>	32 <sup>S</sup>	23 <sup>S</sup>	31 <sup>S</sup>
	EF-CTR 1	CTR	12 <sup>R</sup>	13 <sup>R</sup>	19 <sup>I</sup>	17 <sup>I</sup>	6 <sup>R</sup>	21 <sup>S</sup>	19 <sup>S</sup>	23 <sup>S</sup>
	EF-CTR 2	CTR	13 <sup>R</sup>	6 <sup>R</sup>	6 <sup>R</sup>	6 <sup>R</sup>	33 <sup>S</sup>	27 <sup>S</sup>	22 <sup>S</sup>	28 <sup>S</sup>
	EF-TR	TR	12 <sup>R</sup>	8 <sup>R</sup>	22 <sup>S</sup>	8 <sup>R</sup>	6 <sup>R</sup>	29 <sup>S</sup>	20 <sup>S</sup>	29 <sup>S</sup>
	EF-CAC 1	CAC	11 <sup>R</sup>	11 <sup>R</sup>	20 <sup>I</sup>	12 <sup>R</sup>	30 <sup>S</sup>	26 <sup>S</sup>	19 <sup>S</sup>	26 <sup>S</sup>
	EF-CAC 2	CAC	12 <sup>R</sup>	6 <sup>R</sup>	18 <sup>I</sup>	6 <sup>R</sup>	29 <sup>S</sup>	26 <sup>S</sup>	21 <sup>S</sup>	26 <sup>S</sup>
	EF-CAZ	CAZ	13 <sup>R</sup>	13 <sup>R</sup>	21 <sup>S</sup>	12 <sup>R</sup>	26 <sup>S</sup>	25 <sup>S</sup>	21 <sup>S</sup>	26 <sup>S</sup>

**Note:** The results show the mean of 3 trials rounded to the unit. The standard deviation varied between 0.0 and 1.7. R = Resistant, I = Intermediate, S = sensible, TE = tetracycline, CAZ = ceftazidime, CTR = ceftriaxone, CAC = ceftazidime/clavulanate TR = trimethoprim, CIP = ciprofloxacin, NIT = nitrofurantoin and IMP = imipenem.

### Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC)

The sensitivity of the tested strains to the antimicrobials they were subsequently exposed to was investigated to determine the exact proportions to which these bacteria could be subjected without however killing them. Thus, MICs and MBCs of ampicillin, kanamycin, cefazolin, and silver nanoparticles (AgNPs) were determined (Table 2). The results presented in this table suggest that cefazolin, considering the relatively low MIC and MBC (compared to other antimicrobials) for all the uropathogens used, can be an interesting remedy in the fight against antibiotic resistance. Indeed, broad-spectrum antimicrobials that have not lost their effectiveness despite the increase in the growth of antibiotic resistance can be used as the

last line to limit the damage this phenomenon has on the health of patients and particularly on the prolongation of hospitalizations, an increased medical expenses and mortality. Moreover, specifically for AgNPs, the low MIC (8µg/mL) and MBC (16µg/mL in *E. coli*) suggests that infections caused by this pathogen can easily be treated by AgNPs. These results are in accordance with those observed in previously reported studies [24, 25] but further investigation is needed to confirm such a hypothesis.

Each of the antimicrobials whose MIC and MBC are presented in Table 2 was prepared specifically for each strain at 8 different concentrations varying from MIC/2 to MIC with an increment of MIC/16 for recurrent exposure of Uropathogenic bacteria for 8 days.

Table 2

**Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC)  
of uropathogens to antibiotics and silver nanoparticles to which they have been further exposed**

Strain	MIC ( $\mu\text{g/mL}$ )				MBC ( $\mu\text{g/mL}$ )			
	Ampicillin	Kanamycin	Cefazolin	AgNPs	Ampicillin	Kanamycin	Cefazolin	AgNPs
<i>E. coli</i>	1024	32	32	8	ND	128	64	16
<i>S. aureus</i>	64	8	32	256	128	16	128	512
<i>E. faecalis</i>	32	128	64	256	64	128	64	256
<i>St. agalactiae</i>	32	16	16	256	128	64	32	256

Bacteria long-exposed to antimicrobials do not present the same susceptibility to antibiotics as parent strains.

The use of antibiotics is almost unavoidable in medicine and in other sectors such as agriculture and animal husbandry. However, in recent years concerns have been raised that exposure to antimicrobials (here mainly antibiotics and nanoparticles) can induce cross resistance to other antibiotics [9,10]. In the present study, the changes in the susceptibility to antibiotics were assessed by inhibition diameters as well as the variation rate referring to the original strains and the results were classified as resistant (R), Intermediate (I) or sensitive (S) as defined by the Clinical & Laboratory Standards Institute [13]. As shown in Table 3, antibiotic sensitivity was determined for 4 Uropathogenic strains before and after exposure to ampicillin, kanamycin, cefazolin and silver nanoparticles (AgNPs). For all strains, long exposure to at least one antimicrobial induced acquisition of resistance with a high variation rate in inhibition diameter. Exposure to ampicillin made *E. faecalis* resistant to ceftazidime and *St agalactiae* resistant to tetracycline, ceftazidime/clavulanate and ceftazidime. In addition, following exposure to cefazolin, a significant decrease in susceptibility of *E. coli* to ceftazidime/clavulanate and ceftazidime was observed while *S. aureus* became resistant to ceftazidime/clavulanate, ceftazidime and to ceftriaxone. Similar variations were observed on *St agalactiae* and *E. faecalis*, which in addition to the 3 antibiotics above-mentioned, have become resistant to tetracycline. Moreover, the most significant variations in susceptibility to antibiotics were observed following exposure to kanamycin: On the one hand, *E. coli* developed resistance to ceftazidime and a decrease in sensitivity was noted on ceftazidime/clavulanate and on the other hand *S. aureus*, *E. faecalis* and *St agalactiae* all 3 became resistant to ceftazidime/clavulanate and ceftazidime. Finally, except

for *E. coli* all the bacteria in this investigation which had undergone successive passages in AgNPs developed resistance to ceftazidime/clavulanate and ceftazidime as observed with exposure to other antimicrobials. Surprisingly, the *E. coli* strain that was initially resistant to tetracycline has become sensitive. However, and more globally, the data in this research highlight that long-term exposure to antibiotics and silver nanoparticles may influence susceptibility to other antibiotics in Uropathogenic bacteria. These results are similar to those observed in other studies which consisted in prolonged passage of uropathogens in biocidal agents [9, 26, 27]. It is well known that the sensitivity of bacteria to antibiotics depends mainly on the mode of action of the antimicrobial, the conditions of use and the characteristics of the bacteria tested [28]. However, exposure to low doses of antibiotics can induce significant changes in bacteria which may be phenotypic and/or genotypic. Phenotypically, the potential causes of the changes in susceptibility observed in this study may be structural variations in the bacterial cell [9] which modify bacteria-antimicrobial interactions, inducing changes in membrane permeability and changes in the activity of efflux pumps that allow bacteria to expel antimicrobials out of the cell [29, 30]. Nevertheless, Henly et al. [9] suggested that the exact mechanisms governing a specific adaptation depend largely on the antimicrobial and the bacterium itself. In our study, the reversibility of the acquisition of resistance and the observed variations in susceptibility to antibiotics was not evaluated, but many previous studies on the issue provide contradictories findings. Indeed, while some authors have indicated that the observed changes result from a reversible phenotypic adaptation induced by the expression of variations in gene expression in responses to stress [11], others have noted that these changes after long exposure to antimicrobials are the result of the selection of antimicrobial-resistant mutants with a stable

phenotypic that cannot experience any reversibility [9, 31]. Notwithstanding this divergence of views, it is important to highlight that numerous investigations carried out in both humans and animals show an increase in resistance to antibiotics worldwide [12, 29, 32–34].

Therefore, in addition to further investigations to shed light on the exact mechanism of these changes, further efforts must be made to research new antimicrobials and reposition of existing drug to explore their potential antimicrobial properties.

Table 3

Antibiotic susceptibility of uropathogens before and after successive passages in antibiotics and AgNPs

Strain	Substance	Inhibition zone in mm (variation rate in %) <sup>Sensitivity (R, I, S)</sup>							
		CAC	CIP	TE	CTR	IPM	CAZ	NIT	TR
<i>E. coli</i>	Exposure								
	Initial	22 <sup>S</sup>	24 <sup>S</sup>	8 <sup>R</sup>	25 <sup>S</sup>	27	23 <sup>S</sup>	22 <sup>S</sup>	6 <sup>R</sup>
	Unexposed	22 (0) <sup>S</sup>	21 (-13) <sup>S</sup>	10 (25) <sup>R</sup>	22 (-12) <sup>S</sup>	27 (0) <sup>S</sup>	25 (9) <sup>S</sup>	21 (-5) <sup>S</sup>	6 (0) <sup>R</sup>
	Ampicillin	19 (-14) <sup>S</sup>	23 (-4) <sup>S</sup>	8 (0) <sup>R</sup>	25 (0) <sup>S</sup>	26 (-4) <sup>S</sup>	18 (-22) <sup>S</sup>	20 (-9) <sup>S</sup>	6 (0) <sup>R</sup>
	Cefazolin	16 (-27) <sup>I</sup>	21 (-13) <sup>S</sup>	9 (13) <sup>R</sup>	25 (0) <sup>S</sup>	24 (-11) <sup>S</sup>	16 (-30) <sup>I</sup>	20 (-9) <sup>S</sup>	6 (0) <sup>R</sup>
	Kanamycin	17 (-23) <sup>I</sup>	25 (4) <sup>S</sup>	9 (13) <sup>R</sup>	26 (4) <sup>S</sup>	26 (-4) <sup>S</sup>	12 (-48) <sup>R</sup>	21 (-5) <sup>S</sup>	6 (0) <sup>R</sup>
	AgNPs	20 (-9) <sup>S</sup>	23 (-4) <sup>S</sup>	24 (200) <sup>S</sup>	27 (8) <sup>S</sup>	25 (-7) <sup>S</sup>	19 (-17) <sup>S</sup>	19 (-14) <sup>S</sup>	6 (0) <sup>R</sup>
<i>S. aureus</i>	Initial	16 <sup>I</sup>	26 <sup>S</sup>	12 <sup>R</sup>	25 <sup>S</sup>	29 <sup>S</sup>	12 <sup>R</sup>	21 <sup>S</sup>	6 <sup>R</sup>
	Unexposed	17 (6) <sup>I</sup>	23 (-12) <sup>S</sup>	14 (17) <sup>R</sup>	21 (-16) <sup>S</sup>	26 (-10) <sup>S</sup>	14 (17) <sup>R</sup>	20 (-5) <sup>S</sup>	6 (0) <sup>R</sup>
	Ampicillin	16 (0) <sup>I</sup>	29 (12) <sup>S</sup>	18 (50) <sup>I</sup>	24 (-4) <sup>S</sup>	28 (-3) <sup>S</sup>	13 (8) <sup>R</sup>	23 (10) <sup>S</sup>	6 (0) <sup>R</sup>
	Cefazolin	6 (-63) <sup>R</sup>	25 (-4) <sup>S</sup>	15 (25) <sup>I</sup>	6 (-76) <sup>R</sup>	29 (0) <sup>S</sup>	6 (-50) <sup>R</sup>	22 (5) <sup>S</sup>	6 (0) <sup>R</sup>
	Kanamycin	11 (-31) <sup>R</sup>	16 (-38) <sup>I</sup>	11 (-8) <sup>S</sup>	19 (-24) <sup>I</sup>	24 (-17) <sup>S</sup>	12 (0) <sup>R</sup>	20 (-5) <sup>S</sup>	6 (0) <sup>R</sup>
	AgNPs	12 (-25) <sup>R</sup>	26 (0) <sup>S</sup>	23 (92) <sup>S</sup>	22 (-12) <sup>S</sup>	27 (-7) <sup>S</sup>	11 (-8) <sup>R</sup>	15 (-29) <sup>I</sup>	6 (0) <sup>R</sup>
	Initial	17 <sup>I</sup>	32 <sup>S</sup>	15 <sup>I</sup>	22 <sup>S</sup>	31 <sup>S</sup>	17 <sup>I</sup>	23 <sup>S</sup>	29 <sup>S</sup>
<i>E. faecalis</i>	Unexposed	13 (-24) <sup>R</sup>	27 (-16) <sup>S</sup>	15 (0) <sup>I</sup>	22 (0) <sup>S</sup>	29 (-6) <sup>S</sup>	15 (-12) <sup>I</sup>	21 (-9) <sup>S</sup>	26 (-10) <sup>S</sup>
	Ampicillin	12 (-29) <sup>R</sup>	27 (-16) <sup>S</sup>	15 (0) <sup>I</sup>	24 (9) <sup>S</sup>	28 (-10) <sup>S</sup>	13 (-24) <sup>R</sup>	21 (-9) <sup>S</sup>	27 (-7) <sup>S</sup>
	Cefazolin	6 (-65) <sup>R</sup>	26 (-19) <sup>S</sup>	16 (7) <sup>I</sup>	15 (-32) <sup>I</sup>	26 (-16) <sup>S</sup>	6 (-65) <sup>R</sup>	19 (-17) <sup>S</sup>	24 (-17) <sup>S</sup>
	Kanamycin	6 (-65) <sup>R</sup>	26 (-19) <sup>S</sup>	14 (-7) <sup>R</sup>	14 (-36) <sup>I</sup>	26 (-16) <sup>S</sup>	6 (-65) <sup>R</sup>	22 (-4) <sup>S</sup>	28 (-3) <sup>S</sup>
	AgNPs	12 (-29) <sup>R</sup>	25 (-22) <sup>S</sup>	16 (7) <sup>I</sup>	22 (0) <sup>S</sup>	25 (-19) <sup>S</sup>	12 (-29) <sup>R</sup>	16 (-30) <sup>I</sup>	21 (-28) <sup>S</sup>
	Initial	20 <sup>S</sup>	29 <sup>S</sup>	21 <sup>S</sup>	28 <sup>S</sup>	27 <sup>S</sup>	20 <sup>S</sup>	21 <sup>S</sup>	26 <sup>S</sup>
<i>St. agalactiae</i>	Unexposed	23 (15) <sup>S</sup>	28 (-3) <sup>S</sup>	17 (-19) <sup>I</sup>	22 (-21) <sup>S</sup>	27 (0) <sup>S</sup>	12 (-40) <sup>R</sup>	16 (-24) <sup>I</sup>	27 (4) <sup>S</sup>
	Ampicillin	11 (-45) <sup>R</sup>	25 (-14) <sup>S</sup>	14 (-33) <sup>R</sup>	20 (-29) <sup>I</sup>	26 (-4) <sup>S</sup>	10 (-50) <sup>R</sup>	20 (-5) <sup>S</sup>	28 (8) <sup>S</sup>
	Cefazolin	10 (-50) <sup>R</sup>	22 (-24) <sup>S</sup>	14 (-33) <sup>R</sup>	20 (-29) <sup>I</sup>	24 (-11) <sup>S</sup>	10 (-50) <sup>R</sup>	17 (-19) <sup>I</sup>	27 (4) <sup>S</sup>
	Kanamycin	10 (-50) <sup>R</sup>	27 (-7) <sup>S</sup>	24 (14) <sup>S</sup>	24 (-14) <sup>S</sup>	26 (-4) <sup>S</sup>	10 (-50) <sup>R</sup>	17 (-19) <sup>I</sup>	26 (0) <sup>S</sup>
	AgNPs	12 (-40) <sup>R</sup>	27 (-7) <sup>S</sup>	28 (33) <sup>S</sup>	24 (-14) <sup>S</sup>	30 (11) <sup>S</sup>	13 (-35) <sup>R</sup>	19 (-10) <sup>S</sup>	30 (15) <sup>S</sup>

**Note:** The results show the mean of 3 trials rounded to the unit. The standard deviation varied between 0,3 and 2,1. In bracket ( ) the variation rate calculated by referring to the initial strain. The global variation in each bacterium was significant for  $P \leq 0,05$ . R = Resistant, I = Intermediate, S = sensible, TE = tetracycline, CAZ = ceftazidime, CTR = ceftriaxone, CAC = ceftazidime/clavulanate, TR = trimethoprim, CIP = ciprofloxacin, NIT = nitrofurantoin and IMP = imipenem.

Some bacteria exposed to antibiotics and AgNPs produce more biofilm and planktonic bacteria than control strains.

Biofilms are multicellular communities of microorganisms held together by a self-produced extracellular matrix and are known as a virulence factor and for their involvement in certain pathologies such as catheter infection, cochlear implant infection, wound infection, cochlear implant infection, central nervous system shunt infection, chronic otitis media and pulmonary infection in cystic fibrosis patient [35]. (Gebreyohannes et al., 2019). It is well known that Bacteria that have adapted to the presence


of antimicrobials or biocides agents may exhibit several phenotypic alterations such as changes in growth rate and biofilm formation [9]. In the present study, biofilm formation was assessed by crystal violet bacterial attachment assay. Figures 1 and 2 respectively show the measurements of the formation of biofilms and planktonic bacteria in the 4 bacteria used in this investigation as well as their analogs having undergone passages in ampicillin, kanamycin, cefazolin and silver nanoparticles (AgNPs). Compared to the controls, the *E. coli* and *St agalactiae* strains exposed to ampicillin and cefazolin produced more biofilms while the *E. coli* passed in kanamycin and AgNPs produced

less biofilms. In *S. aureus*, except for the strain passed in ampicillin which produced more biofilms, no significant variation was noted in the formation of biofilms of other exposed strains and in their planktonic bacteria. In addition, the *E. faecalis* strains exposed to AgNPs, Kanamycin and ampicillin produced more biofilms and exhibited a greater quantity of planktonic bacteria. Moreover *E. coli* passed in kanamycin and *E. faecalis* and *St. agalactiae* passed in cefazolin showed relatively low amounts of planktonic bacteria compared to their respective controls. Referring to the results on the susceptibility of strains to antibiotics, contrary to the findings of some authors [1, 9, 36, 37], in this study the increase in biofilm production does not correlate with antibiotic resistance in *E. coli* and other uropathogens. However, it is important to emphasize that exposure to ampicillin induces a considerable increase in biofilm production in all strains tested and this antibiotic should be carefully monitored for its use to treat associated biofilm diseases.


Several bacteria are found in a cluster different from that of the parent strain after an ascending hierarchical

classification taking into account all the parameters studied in this investigation.


Fig. 3 shows the ascending hierarchical classification (AHC) of all strains having undergone exposure to antibiotics or nanoparticles. This HCA was obtained following a principal component analysis including all the parameters evaluated in this study, namely the inhibition diameter and their variation compared to the parent strain, the biofilms formation, and planktonic bacteria as well as their respective variations. As shown in Figure 3, two large clusters were formed. The first cluster (in blue) does not divide into several sub-clusters and groups together bacteria that do not show very significant variations. Thus, in the *E. coli* strain, except those having been exposed to AgNPs, significant variations were not identified. For most of the other bacteria, some were found in the sub-clusters of bacteria from a completely different species and far from their control strains, proof of the significant variations induced by this long exposure to the antimicrobials used.



**Fig. 1.** Biofilm formation in Uropathogenic bacteria exposed or not to antibiotics and silver nanoparticles. The data show the mean absorbance (A<sub>450</sub>) of 12 trials, representative of biofilm formation evaluated by Crystal violet assay for each bacterium after exposure or not to ampicillin (AMP), Cefazolin (CZ), Kanamycin (Ka) and Silver nanoparticles (AgNPs)



**Fig. 2.** Planktonic bacteria in Uropathogenic strains before and after successive exposure to antibiotics and silver nanoparticles. The data show the mean absorbance (A450) of 12 trials, representative of planktonic bacteria evaluated simultaneously with biofilm assay for each bacterium after exposure or not to ampicillin (AMP), Cefazolin (CZ), Kanamycin (Ka) and Silver nanoparticles (AgNPs)



**Fig. 3.** Dissimilarity of uropathogens long exposed or not to antibiotics and nanoparticles. The dendrogram was obtained after a principal component analysis including the Spearman correlation test and considering the susceptibility to antibiotics, the biofilm formation, the planktonic bacteria and the variations of the 3 above-mentioned parameters compared to the initial strains

## Conclusion

The growth of antibiotic resistance is a real danger worldwide. It mainly occurs due to the overuse and misuse of antibiotics. In this study we were able to highlight the possibility of the acquisition of antibiotic resistance in clinical isolates of uropathogens following prolonged exposure to other antibiotics and silver nanoparticles. In addition to the permanent monitoring of the growth of antimicrobial resistance in each zone in order to follow its evolution, permanent efforts must be made to search for new antimicrobials, to reposition the already existing molecules to exploit their antimicrobial properties and to study and better understand specific resistance mechanisms. Finally, to prevent this phenomenon from worsening, it is necessary that any antibiotic prescription be preceded by an antibiogram and that the antibiotics be used only when necessary.

## Библиографический список/ References

1. Penesyan A, Paulsen IT, Gillings MR, Kjelleberg S, Manefield MJ. Secondary Effects of Antibiotics on Microbial Biofilms. *Frontiers in Microbiology*. 2020;11:2109. doi: 10.3389/fmicb.2020.02109.
2. Joseph AMM, Jorelle AB, Sarra S, Podoprigrora IV, Davares AK, Ingrid NK, Carime BZ. Short review on the potential alternatives to antibiotics in the era of antibiotic resistance. *Journal of Applied Pharmaceutical Science*. 2021;12(1):029–040. doi: 10.7324/JAPS.2021.120102.
3. Mbarga MJA, Podoprigrora IV, Davares AKL, Esther N, Senyagin AN. Urinary tract infections: Virulence factors, resistance to antibiotics, and management of uropathogenic bacteria with medicinal plants — A review. *Journal of Applied Pharmaceutical Science*. 2021;11(7):001–012. doi: 10.7324/JAPS.2021.110701.
4. Abraham SN, Miao Y. The nature of immune responses to urinary tract infections. *Nature Reviews Immunology*. 2015; 15(10): 655. DOI: 10.1038/nri3887.
5. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Soper DE. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clinical infectious diseases*. 2011;52(5): e103–e120. doi: 10.1093/cid/ciq257.
6. Bader MS, Loeb M, Leto D, Brooks AA. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. *Postgraduate Medicine*. 2020;132(3):234–250. doi: 10.1080/00325481.2019.1680052.
7. Karam MRA, Habibi M, Bouzari S. Urinary tract infection: Pathogenicity, antibiotic resistance and development of effective vaccines against Uropathogenic Escherichia coli. *Molecular immunology*. 2019;108:56–67. doi: 10.1016/j.molimm.2019.02.007.
8. Lee DS, Lee SJ, Choe HS. Community-acquired urinary tract infection by Escherichia coli in the era of antibiotic resistance. *BioMed research international*. 2018;7656752. doi: 10.1155/2018/7656752.
9. Henly EL, Dowling JAR, Maingay JB, Lacey MM, Smith TJ, Forbes S. Biocide exposure induces changes in susceptibility, pathogenicity, and biofilm formation in uropathogenic Escherichia coli. *Antimicrobial agents and chemotherapy*. 2019;63(3): e01892–18. doi: 10.1128/AAC.01892-18.
10. Blanco P, Hjort K, Martínez JL, Andersson DI. Antimicrobial Peptide Exposure Selects for Resistant and Fit Stenotrophomonas maltophilia Mutants That Show Cross-Resistance to Antibiotics. *MSphere*. 2020;5(5): e00717–20. doi: 10.1128/mSphere.00717-20.
11. Allen MJ, White GF, Morby AP. The response of Escherichia coli to exposure to the biocide polyhexamethylene biguanide. *Microbiology*. 2006;152((Pt 4):989–1000. doi: 10.1099/mic.0.28643-0.
12. Mbarga MJA, Smolyakova LA, Podoprigrora IV, Evaluation of Apparent Microflora and Study of Antibiotic Resistance of Coliforms Isolated from the Shells of Poultry Eggs in Moscow-Russia. *Journal of Advances in Microbiology*. 2020;20(4):70–77. doi: 10.9734/jamb/2020/v20i430242.
13. NCCLS: Clinical & Laboratory Standards Institute. Control methods. Biological and micro-biological factors: Determination of the sensitivity of microorganisms to antibacterial drugs. Federal Center for Sanitary and Epidemiological Surveillance of Ministry of Health of Russia. 2019.
14. Veiga A, Maria da Graça TT, Rossa LS, Mengarda M., Stofella NC, Oliveira LJ, ... Murakami FS. Colorimetric microdilution assay: validation of a standard method for determination of MIC, IC50 %, and IC90 % of antimicrobial compounds. *Journal of microbiological methods*. 2019;162: 50–61. doi: 10.1016/j.mimet.2019.05.003.
15. Manga MJA, Podoprigrora IV, Volina EG, Ermolaev AV, Smolyakova LA. Evaluation of changes induced in the probiotic Escherichia coli M17 following recurrent exposure to antimicrobials. *Journal of Pharmaceutical Research International*. 2021;33(29B):158–167. doi: 10.9734/jpri/2021/v33i29B3160.
16. Arsene MM, Podoprigrora IV, Grigorievna VE, Davares AK, Sergeevna DM, Nikolaevna SI. Prolonged exposure to antimicrobials induces changes in susceptibility to antibiotics, biofilm formation and pathogenicity in staphylococcus aureus. *J. Pharm. Res. Int*. 2022;33(34B):140–151. doi: 10.9734/JPRI/2021/v33i34B31856.
17. Joshi S. Hospital antibiogram: a necessity. *Indian journal of medical microbiology*. 2010;28(4):277. doi: 10.4103/0255-0857.71802.
18. Arsene, M. M., Viktorovna, P. I., Alla, M.V., Mariya, M.A., Sergei, G.V., Cesar, E., ... & Olga, P.V. Optimization of Ethanolic Extraction of Enantia chloranta Bark, Phytochemical Composition, Green Synthesis of Silver Nanoparticles, and Antimicrobial Activity. *Fermentation*. 2022; 8(10): 530. doi: 10.3390/fermentation8100530.
19. Arsene, M. M., Viktorovna, P. I., Sergei, G.V., Hajjar, F., Vyacheslavovna, Y. N., Vladimirovna, Z.A., ... & Sachivkina, N. Phytochemical Analysis, Antibacterial and Antibiofilm Activities of Aloe vera Aqueous Extract against Selected Resistant Gram-Negative Bacteria Involved in Urinary Tract Infections. *Fermentation*. 2022;8(11): 626. doi: 10.3390/fermentation8110626.
20. Windels EM, Van den Bergh B, Michiels J. Bacteria under antibiotic attack: Different strategies for evolutionary adaptation. *PLoS pathogens*. 2020;16(5): e1008431. doi: 10.1371/journal.ppat.1008431.
21. Leonard A, Möhli K, Schlüter R, Taylor E, Lalk M, Methling K. Exploring metabolic adaptation of Streptococcus pneumoniae to antibiotics. *The Journal of antibiotics*. 2020;73(7):441–454. doi: 10.1038/s41429-020-0296-3.
22. Akhova AV, Tkachenko AG. Multifaceted role of polyamines in bacterial adaptation to antibiotic-mediated oxidative stress. *The Microbiological Society of Korea*. 2020;56(2):103–110. doi: 10.7845/kjm.2020.0013.

23. Paun VI, Lavin P, Chifiriuc MC, Purcarea C. First report on antibiotic resistance and antimicrobial activity of bacterial isolates from 13,000-year old cave ice core. *Scientific reports*. 2021;11(1):1–15. doi: 10.1038/s41598-020-79754-5.
24. Devanesan S, Ponmurugan K, AlSalhi MS, Al-Dhabi NA. Cytotoxic and antimicrobial efficacy of silver nanoparticles synthesized using a traditional phytoproduct, asafoetida gum. *International Journal of Nanomedicine*. 2020;15:4351. doi: 10.2147/IJN.S258319.
25. Loo YY, Rukayadi Y, Nor-Khaizura MAR, Kuan CH, Chieng BW, Nishibuchi M, Radu S. In vitro antimicrobial activity of green synthesized silver nanoparticles against selected gram-negative foodborne pathogens. *Frontiers in microbiology*. 2018;9:1555. doi: 10.3389/fmicb.2018.01555.
26. Adamus-Białek W, Wawszczak M, Arabski M, Majchrzak M, Gulba M, Jarych D, Głuszek S. Ciprofloxacin, amoxicillin, and aminoglycosides stimulate genetic and phenotypic changes in uropathogenic *Escherichia coli* strains. *Virulence*. 2019;10(1):260–276. doi: 10.1080/21505594.2019.1596507.
27. Garcia Rivera MA. *Antibiotic uptake in Pseudomonas aeruginosa and its consequences on the metabolome* (Doctoral dissertation, Hannover: Institutionelles Repositorium der Leibniz Universität Hannover); 2021. doi: 10.15488/10509.
28. Naveed M, Chaudhry Z, Bukhari SA, Meer B, Ashraf H. Antibiotics resistance mechanism. In: *Antibiotics and Antimicrobial Resistance Genes in the Environment*. Elsevier. 2020. p.292–312. doi: 10.1016/j.crmicr.2021.100027.
29. Papkou A, Hedge J, Kapel N, Young B, MacLean RC. Efflux pump activity potentiates the evolution of antibiotic resistance across *S. aureus* isolates. *Nature communications*. 2020;11(1):1–15. doi: 10.1038/s41467-020-17735-y.
30. Green AT, Moniruzzaman M, Cooper CJ, Walker JK, Smith JC, Parks JM, Zgurskaya HI. Discovery of multidrug efflux pump inhibitors with a novel chemical scaffold. *Biochimica et Biophysica Acta (BBA)-General Subjects*. 2020;1864(6):129546. doi: 10.1016/j.bbagen.2020.129546.
31. Pokludová L, Prátová H. Wider Context of Antimicrobial Resistance, Including Molecular Biology Perspective and Implications for Clinical Practice. In: Pokludová L., editor. *Antimicrobials in Livestock 1: Regulation, Science, Practice*. Cham: Springer; 2020. p. 233–279. doi: 10.1007/978-3-030-46721-0\_9.
32. WHO. New report calls for urgent action to avert antimicrobial resistance crisis. <https://www.who.int/news/item/29-04-2019-new-report-calls-for-urgent-action-to-avert-antimicrobial-resistance-crisis>. 2019. Accessed 2021 January 28.
33. Banin E, Hughes D, Kuipers OP. Bacterial pathogens, antibiotics and antibiotic resistance. *FEMS microbiology reviews*. 2017;41(3):450–452. doi: 10.1093/femsre/fux016.
34. Saracino IM., Fiorini G, Zullo A, Pavoni M, Saccomanno L, Vaira D. Trends in primary antibiotic resistance in *H. pylori* strains isolated in Italy between 2009 and 2019. *Antibiotics*. 2020;9(1):26. doi: 10.3390/antibiotics9010026.
35. Gebreyohannes G, Nyerere A, Bii C, Sbhatu DB. Challenges of intervention, treatment, and antibiotic resistance of biofilm-forming microorganisms. *Heliyon*. 2019;5(8): e02192. doi: 10.1016/j.heliyon.2019.e02192.
36. Behzadi P, Urbán E, Gajdác M. Association between biofilm-production and antibiotic resistance in uropathogenic *Escherichia coli* (UPEC): an in vitro study. *Diseases*. 2020;8(2):17. doi: 10.3390/diseases8020017.
37. Katongole P, Nalubega F, Florence NC, Asiimwe B, Andia I. Biofilm formation, antimicrobial susceptibility and virulence genes of Uropathogenic *Escherichia coli* isolated from clinical isolates in Uganda. *BMC Infectious Diseases*. 2020;20(1):1–6. doi: 10.1186/s13756-016-0109-4.

## Влияние длительного воздействия субингибирующих доз антибиотиков и наночастиц серебра на уропатогенные бактерии

М.Д.А. Мбарга ✉, Р. Маруф , И.В. Подопригора , К.Л.Д. Аньютулу ,  
Ю.В. Чапурин , И.Н. Шарова 

<sup>1</sup>Медицинский институт, Российский университет дружбы народов, Москва, Российская Федерация  
✉ josepharsenembarga@yahoo.fr

**Аннотация.** Актуальность. В последние годы все более нерациональное использование антибиотиков привело к потере их эффективности. Цель исследования. Настоящее исследование было направлено на изучение изменений, происходящих у уропатогенных бактерий после длительного воздействия противомикробных препаратов. Материалы и методы. Мы оценили влияние длительного воздействия ампициллина, цефазолина, канамицина и наночастиц серебра (AgNP) на чувствительность к другим антибиотикам, образование биопленок и планктонные бактерии у 4 клинических уропатогенных штаммов, а именно *Escherichia coli* (UPEC), *Staphylococcus aureus*, *Enterococcus faecalis* и *Streptococcus agalactiae*. Минимальные ингибирующие концентрации (МИК) определяли с использованием метода микроразведений на микропланшетах, и бактерии подвергали воздействию увеличивающихся концентраций каждого противомикробного препарата (от МИК/2 до МИК) в течение 8 дней. Чувствительность бактерий к антибиотикам оценивали с использованием метода дисковой диффузии Кирби-Бауэра, а образование биопленки оценивали с помощью

анализа прикрепления бактерий кристаллическим фиолетовым. *Результаты и обсуждение.* В результате воздействия ампициллина сделало *E. faecalis* устойчивым к цефтазидиму, а *St agalactiae* — к тетрациклину, цефтазидиму/клавуланату и цефтазидиму. После воздействия цефазолином наблюдалось значительное снижение чувствительности *E. coli* к цефтазидиму/клавуланату и цефтазидиму, в то время как *S. aureus* приобретала устойчивость к цефтазидиму/клавуланату, цефтазидиму и цефтриаксону. Аналогичные вариации наблюдались у *St. agalactiae* и *E. faecalis*, которые в дополнение к трем вышеупомянутым антибиотикам стали устойчивыми к тетрациклину. Наиболее значительные изменения в чувствительности к антибиотикам наблюдались после воздействия канамицина: у *E. coli* развилась устойчивость к цефтазидиму и снижение чувствительности было отмечено к цефтазидиму/клавуланату, в то время как *S. aureus*, *E. faecalis* и *St agalactiae* все 3 стали устойчивыми к цефтазидиму/клавуланату и цефтазидим. Кроме того, за исключением *E. coli*, все бактерии в этом исследовании, подвергшиеся последовательным пассажам в AgNP, выработали устойчивость к цефтазидиму/клавуланату и цефтазидиму. Бактерии, подвергшиеся воздействию ампициллина и цефазолина, продуцировали больше биопленок, чем их соответствующие контроли. *Выводы.* Длительное воздействие антибиотиков и AgNP на уропатогены вызывает значительные изменения в чувствительности к другим антибиотикам и образование биопленок.

**Ключевые слова:** длительное воздействие, антибиотики, наночастицы серебра, биопленка, адаптация

**Информация о финансировании.** Авторы заявляют об отсутствии внешнего финансирования.

**Вклад авторов:** Мбарга М.Д.А. — концепция и дизайн исследования, обзор литературы, обработка данных, сбор и обработка материалов; Подопригора И.В. — оформление исследования, написание текста; Аньютулу К.Л.Д. и Маруф Р. — концепция исследования, обработка данных, сбор и обработка материалов; Чапурин Ю.В. и Шарова И.Н. — статистическая обработка данных, написание текста. Все авторы внесли значительный вклад в разработку концепции, исследования и подготовку рукописи, прочитали и утвердили окончательную версию перед публикацией.

**Информация о конфликте интересов.** Авторы заявляют об отсутствии конфликта интересов.

**Этическое утверждение** — неприменимо.

**Благодарности** — работа выполнена при поддержке Программы стратегического академического лидерства РУДН.

**Информированное согласие на публикацию** — неприменимо.

Поступила 17.11.2022. Принята 15.02.2023.

**Для цитирования:** Mbarga M.J.A., Marouf R., Podoprigora I.V., Anyutoulou K.L.D., Chapurin Y.V., Sharova I.N. Long exposure impact of antibiotics subinhibitory doses and silver nanoparticles on uropathogenic bacteria // Вестник Российского университета дружбы народов. Серия: Медицина. 2023. Т. 27. No 3. С. 391—402. doi: 10.22363/2313-0245-2023-27-2-391-402

*Corresponding author:* Mbarga Manga Joseph Arsene — PhD student, lecturer-assistant in the Department of microbiology named after V.S. Kiktenko, Institute of Medicine, RUDN University, 117198, Miklukho-Maklaya str., 6, Moscow, Russian Federation. E-mail: josepharsenembarga@yahoo.fr  
Mbarga M.J.A. ORCID 0000-0001-9626-9247  
Marouf R. ORCID 0000-0001-9581-5381  
Podoprigora I.V. ORCID 0000-0003-4099-2967  
Anyutoulou K.L.D. ORCID 0000-0001-6219-0004  
Chapurin Y.V. ORCID 0000-0002-3871-9200  
Sharova I.N. ORCID 0000-0002-0932-5376

*Ответственный за переписку:* Мбарга Манга Джозеф Арсен — аспирант и ассистент кафедры микробиологии им. В.С. Киктенко медицинский институт РУДН, Российская Федерация, 117198, г. Москва, ул. Миклухо-Маклая, д. 6.  
E-mail: josepharsenembarga@yahoo.fr  
Мбарга М.Д.А. ORCID 0000-0001-9626-9247  
Маруф Р. SPIN 5385-0884, ORCID 0000-0001-9581-5381  
Подопригора И.В. SPIN 7255-4454, ORCID 0000-0003-4099-2967  
Аньютулу К.Л.Д. ORCID 0000-0001-6219-0004  
Чапурин Ю.В. ORCID 0000-0002-3871-9200  
Шарова И.Н. ORCID 0000-0002-0932-5376